ABN401

Overview

ABN401 is an orally active and selective ATP-competitive c-MET inhibitor with an IC 50 of 10 nM. ABN401 is cytotoxic to MET-addicted cancer cells with the IC 50 of 2-43 nM. ABN401 has bioavailability in rats and dogs of 42.1-56.2% and 27.4-37.7%, respectively. ABN401 has antitumor activity.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-147040
• CAS No.: 2242563-15-9
• Molecular Formula: C29H34N12O
• Molecular Weight: 566.66
• Purity: 98.82%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 1 mg/mL (1.76 mM); Clear solution
• Availability: In-stock

Source

Original product source